Details of the Drug Combination

General Information of Drug Combination (ID: DCBKS3D)

Drug Combination Name
Sivelestat Rufinamide
Indication
Disease Entry Status REF
Chronic myelogenous leukemia Investigative [1]
Component Drugs Sivelestat   DM6BZCV Rufinamide   DMWE60C
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL
High-throughput Screening Result Testing Cell Line: KBM-7
Zero Interaction Potency (ZIP) Score: 20.55
Bliss Independence Score: 20.55
Loewe Additivity Score: 34.56
LHighest Single Agent (HSA) Score: 34.57

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Sivelestat
Disease Entry ICD 11 Status REF
Crohn disease DD70 Phase 3 [2]
Multiple sclerosis 8A40 Phase 3 [2]
Psoriatic arthritis FA21 Phase 3 [2]
Pyoderma gangrenosum EB21 Phase 3 [3]
Rheumatoid arthritis FA20 Phase 3 [2]
Ulcerative colitis DD71 Phase 3 [2]
Anterior uveitis 9A96 Application submitted [4]
Axial spondyloarthritis FA92.0 Application submitted [2]
Sivelestat Interacts with 2 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Pancreatic elastase 1 (CELA1) TT3NKIB CELA1_HUMAN Inhibitor [7]
Neutrophil elastase (NE) TTPLTSQ ELNE_HUMAN Inhibitor [8]
------------------------------------------------------------------------------------
Indication(s) of Rufinamide
Disease Entry ICD 11 Status REF
Epilepsy 8A60-8A68 Approved (orphan drug) [5]
Pediatric lennox-gastaut syndrome 8A62.1 Approved [6]
Seizure disorder 8A6Z Approved [5]
Rufinamide Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Sodium channel unspecific (NaC) TTRK8B9 NOUNIPROTAC Blocker [9]
------------------------------------------------------------------------------------
Rufinamide Interacts with 2 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Carboxylesterase 1 (CES1) DEB30C5 EST1_HUMAN Metabolism [10]
Carboxylesterase 2 (CES2) DETHCPD EST2_HUMAN Metabolism [10]
------------------------------------------------------------------------------------

References

1 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
5 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7470).
6 Clinical pipeline report, company report or official report of Eisai.
7 Sivelestat (selective neutrophil elastase inhibitor) improves the mortality rate of sepsis associated with both acute respiratory distress syndrome... Shock. 2010 Jan;33(1):14-8.
8 Neutrophil elastase inhibitor (sivelestat) reduces the levels of inflammatory mediators by inhibiting NF-kB. Inflamm Res. 2009 Apr;58(4):198-203.
9 Emerging drugs for epilepsy. Expert Opin Emerg Drugs. 2007 Sep;12(3):407-22.
10 Investigation of the metabolism of rufinamide and its interaction with valproate. Drug Metab Lett. 2011 Dec;5(4):280-9.